製品名:4-formyl-3-methoxybenzonitrile

IUPAC Name:4-formyl-3-methoxybenzonitrile

CAS番号:21962-45-8
分子式:C9H7NO2
純度:98%
カタログ番号:CM156985
分子量:161.16

包装単位 有効在庫 価格(USD) 数量
CM156985-500g in stock ȅƴƴƴ

研究開発用専用.

問い合わせフォーム

   refresh    

製品詳細

CAS番号:21962-45-8
分子式:C9H7NO2
融点:-
SMILESコード:N#CC1=CC=C(C=O)C(OC)=C1
密度:
カタログ番号:CM156985
分子量:161.16
沸点:318.2°C at 760 mmHg
MDL番号:MFCD07779491
保管方法:Keep in a tight container and store at 2°C~8°C

Category Infos

Benzenes
Benzene is an important organic compound with the chemical formula C6H6, and its molecule consists of a ring of 6 carbon atoms, each with 1 hydrogen atom. Benzene is a sweet, flammable, colorless and transparent liquid with carcinogenic toxicity at room temperature, and has a strong aromatic odor. It is insoluble in water, easily soluble in organic solvents, and can also be used as an organic solvent itself. The ring system of benzene is called benzene ring, and the structure after removing one hydrogen atom from the benzene ring is called phenyl. Benzene is one of the most important basic organic chemical raw materials. Many important chemical intermediates can be derived from benzene through substitution reaction, addition reaction and benzene ring cleavage reaction.

Column Infos

Finerenone
Bayer announced that FINEARTS-HF met its primary endpoint, achieving a statistically significant reduction of the composite of cardiovascular death and total (first and recurrent) heart failure (HF) events, defined as hospitalizations for HF or urgent HF visits. The randomized, double-blind, placebo-controlled, parallel-group, multi-center phase III cardiovascular outcomes study evaluated the efficacy and safety of KERENDIA® (finerenone) for investigational new use in patients with HF with a LVEF≥40% (left ventricular ejection fraction). Finerenone is a nonsteroidal mineralocorticoid receptor antagonist (MRA) that was approved to reduce the risk of cardiovascular death, non-fatal myocardial infarction, hospitalization for heart failure, sustained eGFR decline, and end-stage kidney disease in adult patients with CKD associated with T2D.
Chemenu has been working to develop more compounds for drug discovery. Here are the building blocks we can provide.